Form 8-K - Current report:
SEC Accession No. 0001104659-24-004800
Filing Date
2024-01-18
Accepted
2024-01-18 16:03:07
Documents
12
Period of Report
2024-01-18
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm243338d1_8k.htm   iXBRL 8-K 28164
  Complete submission text file 0001104659-24-004800.txt   201764

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA espr-20240118.xsd EX-101.SCH 3015
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE espr-20240118_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE espr-20240118_pre.xml EX-101.PRE 22359
6 EXTRACTED XBRL INSTANCE DOCUMENT tm243338d1_8k_htm.xml XML 3329
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35986 | Film No.: 24541780
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)